Andy Ramelmeier

NetSuite EasyDNS Mimecast Outlook Greenhouse.io Google Cloud Hosting Drupal WP Engine Google Font API Google Tag Manager Google Analytics Lever Typekit BugHerd Gravity Forms WordPress.org Mobile Friendly reCAPTCHA Nginx IoT Remote AI

gene therapy biotechnology rare diseases ophthalmology retina life sciences biotechnology: biological products (no diagnostic substances) health care biotechnology research ocular diseases functional cures adeno-associated virus wet age-related macular degeneration single-administration therapy therapeutic proteins efficacy sustained protein expression aav vector technology intravitreal injection chronic disease treatment biological medicines patient accessibility long-lasting treatments anti-vegf therapy blinding diseases ocular biofactories improved patient compliance clinical trials safety profile research & development in-office therapy durable medicines regenerative therapy neovascular amd gmp manufacturing protein dosing therapeutic vectors fda approvals retinal health vision restoration patient-centric care collaboration in healthcare clinical efficacy innovative ophthalmology treatments safety monitoring access to treatment medical innovation vision preservation biofactory approach novel therapeutics healthcare systems disease burden transformative therapies evidence-based decisions inclusivity in research scientific advancements patient quality of life vision loss retinal diseases single-administration therapies neovascular age-related macular degeneration patient-centric innovation scientific excellence proprietary ivt platform clinical-stage development durable treatments genetic disorders healthcare providers patient advocacy pharmaceuticals artemis trial innovative treatments unmet medical needs collaboration partnerships patient demographics evidence-based marketing healthcare stakeholders gene therapy solutions ocular gene therapy patient populations societal impact health wellness & fitness hospital & health care medical